Antidepressants and suicide: risk–benefit conundrums
AUTOR(ES)
Healy, David
RESUMO
There has been a long-standing controversy about the possibility that selective serotonin reuptake inhibitor (SSRI) antidepressants might induce suicidality in some patients. To shed light on this issue, this paper reviews available randomized controlled trials (RCTs), meta-analyses of clinical trials and epidemiological studies that have been undertaken to investigate the issue further. The original clinical studies raising concerns about SSRIs and suicide induction produced evidence of a dose-dependent link on a challenge-dechallenge and rechallenge basis between SSRIs and both agitation and suicidality. Meta-analyses of RCTs conducted around this time indicated that SSRIs may reduce suicidal ideation in some patients. These same RCTs, however, revealed an excess of suicidal acts on active treatments compared with placebo, with an odds ratio of 2.4 (95; confidence interval 1.6–3.7). This excess of suicidal acts also appears in epidemiological studies. The data reviewed here make it difficult to sustain a null hypothesis that SSRIs do not cause problems in some individuals. Further studies or further access to data are indicated to establish the magnitude of any risk and the characteristics of patients who may be most at risk.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=193979Documentos Relacionados
- Updated New Zealand cardiovascular disease risk-benefit prediction guide
- Antidepressants and suicide: what is the balance of benefit and harm
- Medullary thyroid carcinoma – Adverse events during systemic treatment: risk-benefit ratio
- Antidepressants and suicide: Authors' reply
- Antidepressants and suicide: Risk of completed suicide is not the same as risk of deliberate self harm